{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:27:54Z","timestamp":1778754474488,"version":"3.51.4"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In this review, we examine benefits and concerns associated with genetic testing in the clinical management of familial hypercholesterolemia (FH).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Application of next-generation sequencing and other advances provide improved yield of causal mutations compared with older methods and help disclose underlying pathophysiology in many instances. Concerns regarding clinical application of genetic testing remain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>More widespread application of genetic testing for FH in the USA may be forthcoming. When a genetic cause of FH can be identified or is known for the family, test results can provide more accurate individual diagnosis of FH, clarification of underlying pathophysiology, and greater clinical insight. However, several concerns persist, particularly cost to FH patients, potential discrimination, and inappropriate denial of clinically indicated therapies for patients without definitive genetic testing results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000397","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T15:38:54Z","timestamp":1487173134000},"page":"144-151","source":"Crossref","is-referenced-by-count":14,"title":["Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns"],"prefix":"10.1097","volume":"28","author":[{"given":"Paul N.","family":"Hopkins","sequence":"first","affiliation":[{"name":"Cardiovascular Genetics Research Program, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey R.","family":"Lane","sequence":"additional","affiliation":[{"name":"The FH Foundation, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolaemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int J Cardiol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/2047487314533218","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"22","author":"Watts","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"R7-20230917","first-page":"281","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"253","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/jmedgenet-2014-102653","article-title":"Current novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement","volume":"52","author":"Fouchier","year":"2015","journal-title":"J Med Genet"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype\u2013phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"R11-20230917","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw135","article-title":"Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia","author":"Besseling","year":"2016","journal-title":"Eur Heart J"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/CCLM.2008.135","article-title":"Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing","volume":"46","author":"Starr","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: data from the CASCADE-FH Registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2010.213975","article-title":"Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies","volume":"97","author":"Nherera","year":"2011","journal-title":"Heart"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-822992","article-title":"Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands","volume":"4","author":"Wonderling","year":"2004","journal-title":"Semin Vasc Med"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijcard.2014.12.070","article-title":"Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States","volume":"181","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI107331","article-title":"Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.49.3.476","article-title":"Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia","volume":"49","author":"Stone","year":"1974","journal-title":"Circulation"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archinte.1990.00390150076015","article-title":"Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah","volume":"150","author":"Williams","year":"1990","journal-title":"Arch Intern Med"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/clp.10.22","article-title":"Encouraging appropriate treatment for familial hypercholesterolemia","volume":"5","author":"Hopkins","year":"2010","journal-title":"Clin Lipidol"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0021-9150(98)00200-7","article-title":"Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management","volume":"142","year":"1999","journal-title":"Atherosclerosis"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: A 2\u200a\u00d7\u200a2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case\u2013control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","article-title":"Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR\/APOB\/PCSK9 mutations","volume":"51","author":"Futema","year":"2014","journal-title":"J Med Genet"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1373\/clinchem.2014.231365","article-title":"Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries","volume":"61","author":"Futema","year":"2015","journal-title":"Clin Chem"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12471-011-0076-6","article-title":"Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes","volume":"19","author":"Kusters","year":"2011","journal-title":"Neth Heart J"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2004.10.042","article-title":"Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study","volume":"180","author":"Koeijvoets","year":"2005","journal-title":"Atherosclerosis"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1161\/01.CIR.0000041253.61683.08","article-title":"Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population","volume":"106","author":"Umans-Eckenhausen","year":"2002","journal-title":"Circulation"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.atherosclerosis.2009.07.058","article-title":"Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia","volume":"208","author":"Junyent","year":"2010","journal-title":"Atherosclerosis"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCGENETICS.110.959239","article-title":"Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes","volume":"4","author":"Huijgen","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART Registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.110.979450","article-title":"Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children","volume":"123","author":"van der Graaf","year":"2011","journal-title":"Circulation"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2015.07.017","article-title":"Universal screening for familial hypercholesterolemia in children","volume":"66","author":"Klancar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2016.03.025","article-title":"Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland","volume":"249","author":"Mickiewicz","year":"2016","journal-title":"Atherosclerosis"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCGENETICS.112.963587","article-title":"Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort","volume":"5","author":"Ahmad","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacl.2015.09.003","article-title":"Premature coronary heart disease and autosomal dominant hypercholesterolemia: increased risk in women with LDLR mutations","volume":"10","author":"Ahmad","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1399-0004.2008.00999.x","article-title":"Silent exonic mutations in the low-density lipoprotein receptor gene that cause familial hypercholesterolemia by affecting mRNA splicing","volume":"73","author":"Defesche","year":"2008","journal-title":"Clin Genet"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2261-14-108","article-title":"Whole-exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia","volume":"14","author":"Braenne","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/01.ATV.11.5.1349","article-title":"Effects of three genetic loci in a pedigree with multiple lipoprotein phenotypes","volume":"11","author":"Emi","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-148-9-200805060-00022","article-title":"Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations","volume":"148","author":"van der Graaf","year":"2008","journal-title":"Ann Intern Med"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/humu.21660","article-title":"Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels","volume":"33","author":"Huijgen","year":"2012","journal-title":"Hum Mutat"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/ATVBAHA.114.304406","article-title":"PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study","volume":"34","author":"Saavedra","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.atherosclerosis.2011.07.106","article-title":"Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family","volume":"218","author":"Garcia-Garcia","year":"2011","journal-title":"Atherosclerosis"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.11.5.1137","article-title":"Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction","volume":"11","author":"Hopkins","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(99)00212-9","article-title":"Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations","volume":"148","author":"Carmena","year":"2000","journal-title":"Atherosclerosis"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9149(00)01429-6","article-title":"Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia","volume":"87","author":"Hopkins","year":"2001","journal-title":"Am J Cardiol"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jacc.2008.06.050","article-title":"Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting","volume":"52","author":"Civeira","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.atherosclerosis.2015.06.036","article-title":"Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): a reappraisal by using a resequencing approach","volume":"242","author":"Minicocci","year":"2015","journal-title":"Atherosclerosis"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.0000081777.17879.85","article-title":"Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case\u2013control comparison from the National Heart, Lung, and Blood Institute Family Heart Study","volume":"108","author":"Hopkins","year":"2003","journal-title":"Circulation"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s100380050202","article-title":"Co-segregation of elevated LDL with a novel mutation (D92K) of the LDL receptor in a kindred with multiple lipoprotein abnormalities","volume":"45","author":"Wu","year":"2000","journal-title":"J Hum Genet"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diab Endocrinol"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2350-13-87","article-title":"Patient accounts of diagnostic testing for familial hypercholesterolaemia: comparing responses to genetic and nongenetic testing methods","volume":"13","author":"Hollands","year":"2012","journal-title":"BMC Med Genet"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201704000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:21:47Z","timestamp":1694938907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201704000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000397","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}